Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.39 |
| ▸ | RARG | P13631 | 4/20 | 0.39 |
| ▸ | RARA | P10276 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23211841 | 0.83 | PDE4B (0.44) | PDE4BHDAC1HDAC2 | |
| SCHEMBL23149105 | 0.77 | RARA (0.49) | RARBRARGRARARXRA | |
| SCHEMBL30699992 | 0.75 | HSD11B1 (0.39) | PDE4BPDE4APDE4CPDE4DMGLL | |
| SCHEMBL1021435 | 0.71 | RARB (0.56) | RARBRARGRARACNR2PTGS1 | |
| SCHEMBL21381827 | 0.71 | VDR (0.33) | PTGS1PTGS2 | |
| SCHEMBL23212009 | 0.69 | TP53 (0.46) | MGLL | |
| SCHEMBL23149217 | 0.69 | KDM1A (0.42) | RXRA | |
| SCHEMBL1018488 | 0.67 | RARB (0.45) | RARBRARGRARACNR2PTGS1 | |
| SCHEMBL21381825 | 0.67 | TRPM8 (0.34) | RARBRARGRARARXRA | |
| SCHEMBL281668 | 0.67 | TMEM97 (0.44) | RARBRARGRARACNR2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019180185-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | RARB 4457/4885RARG 4531/4885RARA 4518/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | RARB 4457/4885RARG 4531/4885RARA 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.